Leuprolide

CAS 53714-56-0 10 current records 2 historicalProtein

Who holds supplier records for Leuprolide? 10 organisations hold a current record for Leuprolide: an active US FDA Type II Drug Master File or a CEP. A further 2 organisations have only historical (inactive) DMF filings. 10 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: India (2), Netherlands (1), Spain (1), United States (1) and 4 other countries (4); not recorded for 1.

Most records are filed under another form of this substance: Leuprolide Acetate (14 current sources). A DMF or CEP is listed under the form it names.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Leuprolide: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/leuprolide

Reading the evidence

  • 10 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • 7 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Leuprolide expires 22 Dec 2041. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (10)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Leuprolide. Country is the organisation's recorded country, not necessarily the manufacturing site.

Need Leuprolide sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Valid CEP holder entries (10)

Certificates of Suitability on the EDQM register for Leuprolide, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer. 15 certificates in total, including withdrawn, expired, suspended and repeat certificates.

HolderCountryCertificateIssuedEU GMP at holder's address
SUN PHARMACEUTICAL INDUSTRIES LIMITED MumbaiIN
CEP 2014-278 - Rev 02
Leuprorelin
Mar 2026—
POLYPEPTIDE LABORATORIES (SWEDEN) AB LimhamnSE
CEP 2011-321 - Rev 03
Leuprorelin, Process F
Jan 2026Inspected Jan 2025
Sweden
CHEMI S.P.A. PatricaIT
CEP 2008-115 - Rev 05
Leuprorelin
Sept 2025Inspected Jul 2025
Italy
PIRAMAL PHARMA LIMITED Navi MumbaiIN
CEP 2011-274 - Rev 02
Leuprorelin
Mar 2024Inspected May 2024
Italy
BCN PEPTIDES S.A. St Quinti De MedionaES
R1-CEP 2017-193 - Rev 00
Leuprorelin
Dec 2022—
ASPEN OSS B.V. OssNL
R1-CEP 2016-199 - Rev 00
Leuprorelin
Aug 2022—
Takeda Pharmaceutical Company, Limited OsakaJP
R1-CEP 2001-441 - Rev 03
Leuprorelin
Jul 2022—
ZHEJIANG PEPTITES BIOTECH CO., LTD. Sanjie TownCN
R0-CEP 2020-305 - Rev 00
Leuprorelin
Mar 2022—
Bachem AG BubendorfCH
R1-CEP 2001-454 - Rev 01
Leuprorelin
Feb 2009—
PolyPeptide Laboratories Inc. TorranceUS
R1-CEP 2003-045 - Rev 00
Leuprorelin
Feb 2009—

The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.

Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.

Historical records (2)

Organisations whose Type II DMFs for Leuprolide are no longer active. These show a past filing, not current supply.

Show all 2 historical records
  • United States · Inactive DMF 26380 · filed Sept 2012
  • PENINSULA LABS INC
    Inactive DMF 13922 · filed Dec 1998

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (28 listed products contain Leuprolide). The latest listed patent expires 22 Dec 2041. The latest listed exclusivity runs to 25 Aug 2028. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Other forms of this substance

A DMF or CEP is listed under the form it names. Salts, esters and hydrates of the same active substance have their own records:

Overview

Leuprolide is a protein active pharmaceutical ingredient (ChEMBL CHEMBL1201199).

Chemical identity

IUPAC name
(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
Canonical SMILES
CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6
InChIKey
GFIJNRVAKGFPGQ-LIJARHBVSA-N
Synonyms
ABBOTT-43818 FREE BASE, CKD-841, Leuporelin, (-)-leuprolide, Leuprolide, Leuprorelin, Leuprorelina, Leuproreline, Leuprorelin slow release, NSC-377526, TAP-144 FREE BASE, Leuprorelinum

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Leuprolide?

10 organisations hold an active US FDA Type II Drug Master File or a CEP for Leuprolide: ASPEN OSS BV (Netherlands), BCN PEPTIDES SA (Spain), POLYPEPTIDE LABORATORIES INC (United States), BACHEM AG, CHEMI SPA (Italy), Piramal Pharma Limited (India), PolyPeptide Laboratories (Sweden) AB (Sweden) and Sun Pharmaceutical Industries Limited (India), and 2 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Leuprolide Drug Master Files are active?

ASPEN OSS BV (DMF 17243), BCN PEPTIDES SA (DMF 26716) and POLYPEPTIDE LABORATORIES INC (DMF 13150). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Leuprolide records mean?

2 organisations have only inactive Type II DMFs for Leuprolide. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

Does Leuprolide have a European Certificate of Suitability?

Yes. 10 organisations hold a valid CEP for Leuprolide on the EDQM register, including SUN PHARMACEUTICAL INDUSTRIES LIMITED Mumbai (IN), POLYPEPTIDE LABORATORIES (SWEDEN) AB Limhamn (SE), CHEMI S.P.A. Patrica (IT), PIRAMAL PHARMA LIMITED Navi Mumbai (IN), BCN PEPTIDES S.A. St Quinti De Mediona (ES) and ASPEN OSS B.V. Oss (NL) and 4 more. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

Does the FDA Orange Book list patents for products containing Leuprolide?

Yes. The latest patent listed for an approved US product containing Leuprolide expires 22 Dec 2041, across 28 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Leuprolide supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Leuprolide?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.